Maxim analyst Jason Kolbert is out today with a new research note on shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), following the company’s third-quarter results and update on its clinical progress. Kolbert rates CTRV shares a Buy with a $4.00 price target, which implies an upside of 656% from current levels.
Kolbert wrote, “In a letter to shareholders last week, management highlighted the intense focus on HBV with TXL and CRV431. The company also noted the changing landscape in Shingles which is likely a key factor in the decision to stop the development of Valnivudine which was being developed for post-herpetic neuralgia.”
The bottom line: “Contravir is focused on finding HBV. TXL represents a backbone therapy in the space and with CRV431 may create new synergies in developing a functional cure. The MOAs are different, but may be synergistic as they target HBV at different stages of the viral life cycle. TXL works to reduce HBV viral load in the blood stream while CRX431 inhibits both HBx and HBsAg from interacting with CyPA.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a yearly average return of -8.0% and a 33.9% success rate. Kolbert has a -36.8% average return when recommending CTRV, and is ranked #4635 out of 4701 analysts.
Overall, the 2 analysts polled in the past 12 months rate ContraVir stock a Buy. With a return potential of 656%, the stock’s consensus target price stands at $4.00.